Detecting and treating common sexually transmitted diseases

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 5, 2009, Pages 647-660

  Hay, Phillip ^a   Ugwumadu, Austin ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

candidiasis; pelvic inflammatory disease; sexually transmitted infections

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; BORIC ACID; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLOTRIMAZOLE; DOXYCYCLINE; FAMCICLOVIR; FLUCONAZOLE; IMIQUIMOD; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE; OFLOXACIN; PENICILLIN G; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TINIDAZOLE; VALACICLOVIR; WART VIRUS VACCINE; ANTIINFECTIVE AGENT;

ANAMNESIS; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDIAL URETHRITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GENITAL HERPES; GONORRHEA; HUMAN; MICROBIOLOGICAL EXAMINATION; MYCOPLASMA GENITALIUM; MYCOPLASMOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PATHOGENESIS; PELVIC INFLAMMATORY DISEASE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; SERODIAGNOSIS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYPHILIS; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; UTERINE CERVIX CANCER; VAGINA CANDIDIASIS; VAGINITIS; FEMALE; MICROBIOLOGY; PHYSICAL EXAMINATION; PROCEDURES; SEXUALLY TRANSMITTED DISEASES;

ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; MEDICAL HISTORY TAKING; PELVIC INFLAMMATORY DISEASE; PHYSICAL EXAMINATION; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES;

EID: 69249221356     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2009.06.008     Document Type: Article

References (74)

1. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections overview and estimates (2001), World Health Organization, Geneva. http://www.who.int/docstore/hiv/GRSTI/who_hiv_aids_2001.02.pdf Available from:
2. Hill-Jones B., and Noble R. STD Statistics Worldwide. Available from: (2009). http://www.avert.org/stdstatisticsworldwide.htm AVERT. 16-3-2009
3. Simms I., Fenton K.A., Ashton M., et al. The re-emergence of syphilis in the United Kingdom: the new epidemic phases. Sex Transm Dis 32 4 (2005) 220-226
4. Erens B., McManus S., Field J., et al. NATSAL 2000: National Survey of Sexual Attitudes and Lifestyles (26-11-2002), National Centre for Social Research. Available from: http://qb.soc.surrey.ac.uk/surveys/nssal/nssal00.htm#one
5. Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 RR-11 (2006) 1-94
6. Clinical Effectiveness Group B. STD treatment guidelines. Available from: (2009). http://www.bashh.org/groups/clinical_effectiveness_group
7. Grosskurth H., Mosha F., Todd J., et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 346 8974 (1995) 530-536
8. Bosu W.K. Syndromic management of sexually transmitted diseases: is it rational or scientific?. Trop Med Int Health 4 2 (1999) 114-119
9. Young H. Syphilis. Serology. Dermatol Clin 16 4 (1998) 691-698
10. Kingston M., French P., Goh B., et al. UK national guidelines on the management of syphilis 2008. Int J STD AIDS 19 11 (2008) 729-740
11. Palmer H.M., Higgins S.P., Herring A.J., et al. Use of PCR in the diagnosis of early syphilis in the United Kingdom. Sex Transm Infect 79 6 (2003) 479-483
12. Augenbraun M., and Workowski K. Ceftriaxone therapy for syphilis: report from the emerging infections network. Clin Infect Dis 29 5 (1999) 1337-1338
13. Riedner G., Rusizoka M., Todd J., et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 353 12 (2005) 1236-1244
14. Lukehart S.A., Godornes C., Molini B.J., et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 351 2 (2004) 154-158
15. Screening Guidelines Steering Committee CEG. Sexually Transmitted Infections: UK National Screening and Testing Guidelines. 2006.
16. Cook R.L., Hutchison S.L., Ostergaard L., et al. Systematic review: noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 142 11 (2005) 914-925
17. Whiley D.M., Tapsall J.W., and Sloots T.P. Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn 8 1 (2006) 3-15
18. Whiley D.M., Garland S.M., Harnett G., et al. Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health 5 1 (2008) 17-23
19. Ripa T., and Nilsson P.A. A Chlamydia trachomatis strain with a 377-bp deletion in the cryptic plasmid causing false-negative nucleic acid amplification tests. Sex Transm Dis 34 5 (2007) 255-256
20. Newman L.M., Moran J.S., and Workowski K.A. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 44 Suppl. 3 (2007) S84-S101
21. Workowski K.A., Berman S.M., and Douglas Jr. J.M. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 148 8 (2008) 606-613
22. Delpech V., Martin I.M., Hughes G., et al. Epidemiology and clinical presentation of gonorrhoea in England & Wales: findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme 2001-2006. Sex Transm Infect (2009)
23. Chisholm S.A., Neal T.J., Alawattegama A.B., et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother (2009)
24. Barry P.M., and Klausner J.D. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 10 4 (2009) 555-577
25. Ross J.D., and Jensen J.S. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect 82 4 (2006) 269-271
26. Jensen J.S., Bradshaw C.S., Tabrizi S.N., et al. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis 47 12 (2008) 1546-1553
27. Johnston V.J., and Mabey D.C. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 21 1 (2008) 56-64
28. Wiese W., Patel S.R., Patel S.C., et al. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med 108 4 (2000) 301-308
29. Nanda N., Michel R.G., Kurdgelashvili G., et al. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther 4 1 (2006) 125-135
30. Clinical Effectiveness Group (British Association for Sexual Health and HIV). 2007 national guideline for the management of Genital Herpes. Available from: (2007). http://www.bashh.org/documents/115/115.pdf
31. Hollier L.M., and Wendel G.D. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev (2008) (1):CD004946
32. Lebrun-Vignes B., Bouzamondo A., Dupuy A., et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 57 2 (2007) 238-246
33. Gill N., Davies E.J., and Ashkar A.A. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am J Reprod Immunol 59 1 (2008) 35-43
34. Nurbhai M., Grimshaw J., Watson M., et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev (2007) (4):CD002845
35. Fidel Jr. P.L. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 57 1 (2007) 2-12
36. Babula O., Lazdane G., Kroica J., et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 37 5 (2003) 733-737
37. Sobel J.D., Wiesenfeld H.C., Martens M., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 351 9 (2004) 876-883
38. Sobel J.D. Management of recurrent vulvovaginal candidiasis: unresolved issues. Curr Infect Dis Rep 8 6 (2006) 481-486
39. Sobel J.D., Chaim W., Nagappan V., et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 189 5 (2003) 1297-1300
40. Fredricks D.N., and Marrazzo J.M. Molecular methodology in determining vaginal flora in health and disease: its time has come. Curr Infect Dis Rep 07 (2005) 463-470
41. Fredricks D.N., Fiedler T.L., Thomas K.K., et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 45 10 (2007) 3270-3276
42. Koumans E.H., Markowitz L.E., and Hogan V. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 35 Suppl. 2 (2002) S152-S172
43. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis 22 (2009) 82-86
44. Swidsinski A., Mendling W., Loening-Baucke V., et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 198 1 (2008) 97 e1-e6
45. Swidsinski A., Mendling W., Loening-Baucke V., et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 106 5 Pt 1 (2005) 1013-1023
46. Josey W.E., and Schwebke J.R. The polymicrobial hypothesis of bacterial vaginosis causation: a reassessment. Int J STD AIDS 19 3 (2008) 152-154
47. Hay P.E., and Taylor-Robinson D. Reassessment of BV causation. Int J STD AIDS 19 9 (2008) 646-647
48. Verstraelen H. Bacterial vaginosis: a sexually enhanced disease. Int J STD AIDS 19 8 (2008) 575-576
49. Simms I., Eastick K., Mallinson H., et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol 56 (2003) 616-618
50. Cohen C.R., Manhart L.E., Bukusi E.A., et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 359 (2002) 765-766
51. Wiesenfeld H.C., Hillier S.L., Krohn M.A., et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 100 (2002) 456-463
52. Gareen I.F., Greenland S., and Morgenstern H. Intrauterine devices and pelvic inflammatory disease: meta-analyses of published studies, 1974-1990. Epidemiology 11 (2000) 589-597
53. Stevenson M.M., and Radcliffe K.W. Preventing pelvic infection after abortion. Int J STD AIDS 6 (1995) 305-312
54. McNabb P.C., and Tomasi T.B. Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol 31 (1981) 477-496
55. Lake A.M., Bloch K.J., Neutra M.R., et al. Intestinal goblet cell mucus release. II. In vivo stimulation by antigen in the immunized rat. J Immunol 122 (1979) 834-837
56. Mulks M.H., and Plaut A.G. IgA protease production as a characteristic distinguishing pathogenic from harmless Neisseriaceae. N Engl J Med 299 (1978) 973-976
57. Magnusson K.E., Stendahl O., Stjernstrom I., et al. Reduction of phagocytosis, surface hydrophobicity and charge of Salmonella typhimurium 395 MR10 by reaction with secretory IgA (SIgA). Immunology 36 (1979) 439-447
58. McGee Z.A., Johnson A.P., and Taylor-Robinson D. Pathogenic mechanisms of Neisseria gonorrhoeae: observations on damage to human fallopian tubes in organ culture by gonococci of colony type 1 or type 4. J Infect Dis 143 (1981) 413-422
59. Gregg C.R., Melly M.A., Hellerqvist C.G., et al. Toxic activity of purified lipopolysaccharide of Neisseria gonorrhoeae for human fallopian tube mucosa. J Infect Dis 143 (1981) 432-439
60. Melly M.A., McGee Z.A., and Rosenthal R.S. Ability of monomeric peptidoglycan fragments from Neisseria gonorrhoeae to damage human fallopian-tube mucosa. J Infect Dis 149 (1984) 378-386
61. Ness R.B., Brunham R.C., Shen C., et al. Associations among human leukocyte antigen (HLA) class II DQ variants, bacterial sexually transmitted diseases, endometritis, and fertility among women with clinical pelvic inflammatory disease. Sex Transm Dis 31 (2004) 301-304
62. Rice P.A., and Schachter J. Pathogenesis of pelvic inflammatory disease. What are the questions?. J Am Med Assoc 266 (1991) 2587-2593
63. Ness R.B., Soper D.E., Holley R.L., et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. Am J Obstet Gynecol 185 (2001) 121-127
64. Rothman K.J., Funch D.P., Alfredson T., et al. Randomized field trial of vaginal douching, pelvic inflammatory disease and pregnancy. Epidemiology 14 (2003) 340-348
65. Stamm W.E., Guinan M.E., Johnson C., et al. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 310 (1984) 545-549
66. Westrom L.V. Sexually transmitted diseases and infertility. Sex Transm Dis 21 (1994) S32-S37
67. Sellors J., Mahony J., Goldsmith C., et al. The accuracy of clinical findings and laparoscopy in pelvic inflammatory disease. Am J Obstet Gynecol 164 (1991) 113-120
68. Westrom l & Mardh PA. Acute pelvic inflammatory disease. In: Holmes KK, Mardh PA, Sparlling PF & Weisner PJ (eds). Sexually Transmitted Diseases. 2nd ed. NewYork: McGraw-Hill, 1990, pp. 593-613.
69. Simms I., Warburton F., and Westrom L. Diagnosis of pelvic inflammatory disease: time for a rethink. Sex Transm. Infect 79 (2003) 491-494
70. Yudin M.H., Hillier S.L., Wiesenfeld H.C., et al. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol 188 (2003) 318-323
71. Kiviat N.B., Wolner-Hanssen P., Eschenbach D.A., et al. Endometrial histopathology in patients with culture-proved upper genital tract infection and laparoscopically diagnosed acute salpingitis. Am J Surg Pathol 14 (1990) 167-175
72. Ross J.D. An update on pelvic inflammatory disease. Sex Transm Infect 78 (2002) 18-19
73. Singh A., Danrad R., Hahn P.F., et al. MR imaging of the acute abdomen and pelvis: acute appendicitis and beyond. Radiographics 27 (2007) 1419-1431
74. Royal College of Obstetricians & Gynaecologists. Green-top Guideline. Management of acute pelvic inflammatory disease. Guideline Number 32, London, 2008. pp. 1-11.